Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
25 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Affimed Therapeutics AG - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Affimed Therapeutics AG - Product Pipeline Review - 2015', provides an overview of the Affimed Therapeutics AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Affimed Therapeutics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Affimed Therapeutics AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Affimed Therapeutics AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Affimed Therapeutics AG's pipeline products Reasons To Buy - Evaluate Affimed Therapeutics AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Affimed Therapeutics AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Affimed Therapeutics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Affimed Therapeutics AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Affimed Therapeutics AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Affimed Therapeutics AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Affimed Therapeutics AG Snapshot 4 Affimed Therapeutics AG Overview 4 Key Information 4 Key Facts 4 Affimed Therapeutics AG - Research and Development Overview 5 Key Therapeutic Areas 5 Affimed Therapeutics AG - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Affimed Therapeutics AG - Pipeline Products Glance 9 Affimed Therapeutics AG - Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 Affimed Therapeutics AG - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Affimed Therapeutics AG - Drug Profiles 12 AFM-13 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 AFM-11 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AFM-21 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Monoclonal Antibodies for Multiple Myeloma 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Affimed Therapeutics AG - Pipeline Analysis 16 Affimed Therapeutics AG - Pipeline Products by Target 16 Affimed Therapeutics AG - Pipeline Products by Route of Administration 17 Affimed Therapeutics AG - Pipeline Products by Molecule Type 18 Affimed Therapeutics AG - Pipeline Products by Mechanism of Action 19 Affimed Therapeutics AG - Recent Pipeline Updates 20 Affimed Therapeutics AG - Dormant Projects 22 Affimed Therapeutics AG - Locations And Subsidiaries 23 Head Office 23 Other Locations & Subsidiaries 23 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 24 Disclaimer 25
List of Tables Affimed Therapeutics AG, Key Information 4 Affimed Therapeutics AG, Key Facts 4 Affimed Therapeutics AG - Pipeline by Indication, 2015 6 Affimed Therapeutics AG - Pipeline by Stage of Development, 2015 7 Affimed Therapeutics AG - Monotherapy Products in Pipeline, 2015 8 Affimed Therapeutics AG - Phase II, 2015 9 Affimed Therapeutics AG - Phase I, 2015 10 Affimed Therapeutics AG - Preclinical, 2015 11 Affimed Therapeutics AG - Pipeline by Target, 2015 16 Affimed Therapeutics AG - Pipeline by Route of Administration, 2015 17 Affimed Therapeutics AG - Pipeline by Molecule Type, 2015 18 Affimed Therapeutics AG - Pipeline Products by Mechanism of Action, 2015 19 Affimed Therapeutics AG - Recent Pipeline Updates, 2015 20 Affimed Therapeutics AG - Dormant Developmental Projects,2015 22 Affimed Therapeutics AG, Subsidiaries 23
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.